Contact SCGE




Clinical Trial Report

Gene Therapy Trial Report

Summary

EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)


NCTID NCT05444894 (View at clinicaltrials.gov)
Description
Development Status Inactive
Indication Beta-Thalassemia Major
Disease Ontology Term DOID:0080771
Compound Name EDIT-301
Compound Alias Renizgamglogene autogedtemcel
Sponsor Editas Medicine, Inc.
Funder Type Industry
Recruitment Status
Active not recruiting
Enrollment Count 9
Results Posted Not Available

Therapy Information


Target Gene/Variant HBG1/HBG2
Therapy Type Gene editing
Therapy Route Ex-vivo
Mechanism of Action Overexpression of protective allele/gene
Route of Administration Intravenous
Drug Product Type Autologous cells
Target Tissue/Cell CD34+ cells
Delivery System Viral transduction
Vector Type LV
Editor Type ASCas12a mRNA
Dose 1 Min: 5.7E6 CD34+ cells/kg
Dose 2 Max: 11.9E6 CD34+ cells/kg
Dose 3
Dose 4
Dose 5

Study Record Dates


Current Stage Phase1, Phase2
Submit Date 2022-06-27
Completion Date 2025-12
Last Update 2025-04-02

Participation Criteria


Eligible Age 18 Years - 35 Years
Standard Ages Adult
Sexes Eligible for Study ALL

Locations


No.of Trial Sites 8
Locations Canada,United States

Regulatory Information


Has US IND True
FDA Designations Regenerative Medicine Advanced Therapy
Recent Updates Ended development of this program due to inability to locate a financial partner

Resources/Links